Novartis AG





Market Closed - Swiss Exchange 11:30:33 2024-07-15 EDT 5-day change 1st Jan Change
99.1 CHF -0.96% Intraday chart for Novartis AG +1.93% +16.77%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Brace for a flurry of speeches from Fed officials Our Logo
European companies cut jobs as economy sputters RE
MorphoSys Informs Nasdaq Stock Market of Delisting Plans After Novartis Merger MT
S&P 500 Rises Week-to-Week, Closes Near Highs Despite Mixed Inflation Data, Bank Earnings MT
Novartis Seeks Squeeze Out Approval at MorphoSys AGM MT
Global markets live: KKR, Apple, Tesla, Oracle, McDonald's... Our Logo
Novartis to Close Technical Research Facility in San Diego, California; 100 Jobs Affected MT
Novartis to Close Research Facility in San Diego, California; 100 Jobs Affected MT
Markets Powered by Alternating Current Our Logo
NOVARTIS AG : Deutsche Bank reiterates its Buy rating ZD
SIX to Cap SLI Index Weight of Nestle, Novartis Roche, UBS MT
European companies cut jobs as economy sputters RE
Lexicon Pharmaceuticals Names Mike Exton CEO, Jeff Wade Operating Chief MT
Novo Nordisk Reprimanded in UK Over Undisclosed Payments; Novartis, Pfizer Found in Breach of Industry Code MT
UK Pharmaceutical Trade Group Slams Novartis, Three Others for Breaches MT
NOVARTIS AG : Berenberg sticks Neutral ZD
Carisma Therapeutics Notifies Novartis Pharmaceuticals of Terminated Manufacturing, Supply Agreement DJ
NOVARTIS AG : Receives a Buy rating from Jefferies ZD
NOVARTIS AG : Deutsche Bank reiterates its Buy rating ZD
Fitch Affirms Novartis Ratings on Leading Position in Innovative Pharmaceutical Sector MT
Amneal Pharmaceuticals to Develop Omalizumab Biosimilar for Allergy Treatments MT
New semester, new state of mind Our Logo
NOVARTIS AG : Gets a Buy rating from Goldman Sachs ZD
Foreign banks target Switzerland after UBS takeover of Credit Suisse RE
NOVARTIS AG : Barclays reaffirms its Sell rating ZD
Chart Novartis AG
More charts
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
111.9 USD
Average target price
112.6 USD
Spread / Average Target
  1. Stock Market
  2. Equities
  3. NOVN Stock
  4. News Novartis AG
  5. AlphaValue/Baader Europe Lowers Price Target on Novartis, Maintains Add Recommendation